Medical Advocates for Social Justice
Conference Abstract
from the
4th International Workshop on the Clinical Pharmacology
of HIV Therapy

Cannes, France  March 27-29, 2003
 

 
Lack of drug-drug interaction between lopinavir
and saquinavir based on their trough plasma
concentrations  in highly HIV-experienced patients
treated with Kaletra and Invirase.  
 
JM Poirier 1, O Zouai 1, JL Meynard 2, et al
1 Department of Pharmacology, Saint-Antoine University Hospital,
Paris, France
2 Department of Infectious Diseases, Saint-Antoine University Hospital,
Paris, France , 		  
Share this Abstract with a Colleague
 
Background:
A double boosted PIs regimen including Lopinavir/r in addition to saquinavir can be used in patients experiencing multiple treatment failures. The objective of the study was to evaluate steady-state trough plasma concentrations of lopinavir (LPV), saquinavir (SQV) and ritonavir (RTV) administered as triple PI combination in highly pretreated HIV- patients.

Methods:
In eight HIV-pretreated patients receiving in combination SQV (Invirase) and LPV/r (600 mg SQV + 400/100 mg LPV/RTV bid) plus nucleoside analogues (NRTIs), trough PIs plasma concentrations (Cmin) obtained 10-14h after the last drug intake were analyzed using of a validated HPLC method. These plasma concentrations were retrospectively compared to those of a reference population receiving either 600/100 mg SQV/RTV bid or 400/100 mg LPV/RTV bid in combination with NRTIs. Non parametric tests were used for statistical significance.

Results:
Cmin SQV and Cmin LPV were not statistically modified when these PIs were coadministered. RTV Cmin was also similar in patients receiving 400/100 LPV/r alone and the studied combination. As compared to patients receiving boosted saquinavir alone, RTV Cmin was significantly decreased in patients receiving either LPV/r or SQV in presence of LPV/r.

Conclusion:
These data show that LPV and SQV Cmin were unaffected when these PIs were coadministred despite a decrease in RTV plasma concentrations. Saquinavir with lopinavir/r plus nucleosides can be a suitable combination in highly pretreated patients.
Main New/Newsworthy KLS Clinical Pharm Main Page Cannes Conference Index      
Lack of drug-drug interaction between lopinavir and saquinavir based on their trough plasma concentrations in highly HIV-experienced patients treated with Kaletra and Invirase.
4th International Workshop on the Clinical Pharmacology
of HIV Therapy
A Medical Advocates for Social Justice Update